<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00653393</url>
  </required_header>
  <id_info>
    <org_study_id>04-0413-001</org_study_id>
    <nct_id>NCT00653393</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Tranylcypromine 10mg Tablets Under Fasting Conditions</brief_title>
  <official_title>To Compare Bioavailability of Kali Tranylcypromine 10mg Tablets to That of Parnate 10 mg Tablets Under Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Par Pharmaceutical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SFBC Ft. Myers, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Par Pharmaceutical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the single-dose Bioavailability of Tranylcypromine and Parnate
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the relative Bioavailability of Tranylcypromine 10 mg tablets with that of PARNATE
      10mg tablets in normal,healthy, men and women under fasting conditions
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">December 2004</completion_date>
  <primary_completion_date type="Actual">November 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and Extend of Absorption</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>To Determine the Bioavailability of Tranylcypromine</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received Kali product under fasting conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received Parnate product under fasting conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranylcypromine</intervention_name>
    <description>Tablets, 10 mg, single-dose</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Parnate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Parnate</intervention_name>
    <description>Tablets, 10 mg, single-dose</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Tranylcypromine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects will be normal, healthy adult men and women who volunteer to participate.

          -  Is the individual healthy, nonsmoking, normal adult man or woman who volunteers to
             participate?

          -  Is s/he at least 18 years of age? Is his/her BMI between 19 and 30, exclusive?

          -  Is she willing to avoid pregnancy by abstaining from sexual intercourse, or by the use
             of barrier methods. (diaphragm, condom, foams/jellies, sponge), and IUD, or has she
             has been surgically sterile or post- menopausal at least six months prior to entering
             into the study?

          -  Is s/he considered reliable and capable of understanding his/her responsibility and
             role in the study?

          -  Has/s/he provided written informed consent?

          -  A no answer to any of the above questions indicates taht the individual is ineligible
             for enrollment.

        Exclusion Criteria:

          -  Does the individual have a history of allergy or hypersensitivity to tranylcypromine?

          -  Does/ s/he have clinically significant laboratory abnormalities that would interface
             with the conduct or interpretation of the study or jeopardize his/her safety?

          -  Does s/he have significant history or clinical evidence of auto-immune,
             cardiovascular, gastrointestinal, hematopoietic, hepatic, neurological, ongoing
             infection, pancreatic, or renal diseases that would interface with the conduct or
             interpretation of the study or jeopardize his/her safety?

          -  Is she nursing?

          -  Does s/he have serious psychological illness?

          -  Does s/he have significant history ( within the past year) or clinical evidence of
             alcohol or drug abuse?

          -  Does s/he have a positive urine drug screen or saliva alcohol screen, or a positive
             HIV-1 , or hepatitis B or C screen, or a positive pregnancy test?-Is s/he unable to
             refrain from the use of alcohol or xanthine-containing foods or beverages during
             periods beginning 48 hours prior to study drug administration and ending when the alst
             blood sample has been taken?

          -  Is s/he unable to refrain from the ingestion of smoked meat, cheese (except cream
             cheese and cottage cheese), wine and beer during periods beginning 48 hours prior to
             study initiation and ending seven days after the last blood sample has been taken in
             study period two?

          -  Has s/he used any prescription drug during the 14-day period prior to study
             initiation, or any OTC drug during the 72-hour period preceding study initiation?

          -  Is s/he unable to refrain from the use of all concomitant medications during the
             study?

          -  Ha s/he donated or lost blood, or participated in a clinical study which involved the
             with drawl of a large volume of blood (480mL or more), during the six week period
             preceding study initiation?

          -  Has s/he donated an investigational drug during the 30 day period preceding study
             initiation?

          -  A yes answer to any of the above questions indicates that the individual is ineligible
             for enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Pizzaro</last_name>
    <role>Principal Investigator</role>
    <affiliation>SFBC Ft. Myers, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SFBC Ft. Myers, Inc</name>
      <address>
        <city>Ft. Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2008</study_first_submitted>
  <study_first_submitted_qc>April 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2008</study_first_posted>
  <last_update_submitted>April 3, 2008</last_update_submitted>
  <last_update_submitted_qc>April 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Alfred Elvin/ Director Biopharmaceutics</name_title>
    <organization>Par Pharmaceutical, Inc.</organization>
  </responsible_party>
  <keyword>bioequivalence, single- dose, fasting</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranylcypromine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

